Tag - Cognoptix

Cognoptix CEO Dr. Susanne Wilke to Present at the 13th Annual BIOTECH SHOWCASE™ DIGITAL Event

Ziad2022-11-25T14:02:04-05:00 Cognoptix, a privately-held, diagnostics company with a breakthrough technology for the early detection of Alzheimer's disease (AD), announces that the company will present at the 13th Annual Biotech Showcase™ Digital Event, January 11-15, 2021. Read more >>

Cognoptix Appoints New Chief Medical Officer, Dr. Carl Sadowsky, MD, And Chief Financial Officer, Mike Kaswan, MBA, To Management Team

Ziad2022-11-25T14:02:04-05:00 Cognoptix, a leading diagnostics company dedicated to the early detection of Alzheimer's disease (AD), announces two appointments to its senior management team. Dr. Carl H. Sadowsky, MD will serve as the company's new Chief Medical Officer (CMO) and Mike Kaswan, MBA will be Cognoptix's Chief Financial Officer (CFO). Read more >>

Cognoptix Announces Formation of a New Board of Directors

Ziad2022-11-25T14:02:04-05:00 Cognoptix is a breakthrough diagnostics company developing an innovative office-based device-drug system for the early detection of Alzheimer's disease (AD). As another milestone of the Series R restart, recapitalization, and revitalization, the company named a new Board of Directors (BOD) formed under the leadership of Dr. Susanne Wilke, Ph.D., Cognoptix' new President and CEO. Read more >>

Cognoptix Co-Founder Lee Goldstein, M.D., Ph.D. Joins Cognoptix Board of Directors and Scientific Advisory Board

Ziad2022-11-25T14:02:04-05:00 Cognoptix, a leading healthcare company for early-stage detection of Alzheimer's disease (AD), announces its co-founder, Lee Goldstein, M.D., Ph.D. has joined Cognoptix's Scientific Advisory Board, serving as Co-Chair, and the company's Board of Directors. Read more >>

Cognoptix Announces New Scientific Advisory Board with Alzheimer’s Research Leaders

Ziad2022-11-25T14:02:05-05:00 Cognoptix, a leading diagnostics company dedicated to early detection of Alzheimer's disease (AD), announced today the formation of its new Scientific Advisory Board (SAB) with appointment of five world-class scientists and clinical researchers in AD. The SAB includes Jeffrey L. Cummings, MD, ScD; Lee E. Goldstein, MD, PhD; Philip Scheltens, MD, PhD; Martin R. Farlow, MD; and Carl H. Sadowsky, MD. Drs. Cummings and Goldstein will serve as SAB Clinical and Science Chairs, respectively. Read more >>

Cognoptix Revitalizes, Appoints New Chief Executive Officer Dr. Susanne Wilke, PhD, Raises Oversubscribed $2.6m Series R

Ziad2022-11-25T14:02:27-05:00 Cognoptix, a healthcare company developing the Sapphire II System, a breakthrough technology for early detection of Alzheimer's disease (AD), announces the closing of an over-subscribed Series R financing round. Cognoptix has undergone a complete revitalization over the past year. Read more >>

Cognoptix developing an Alzheimer’s disease test using the eye

Ziad2022-11-25T14:02:39-05:00 Cognoptix Inc CEO Susanne Wilke sat down with Proactive's Christine Corrado at the Biotech Showcase 2020 in San Francisco. The Concord, Massachusetts-based company develops non-invasive eye tests for the early diagnosis of Alzheimer's disease. Read more >>